Proton pump inhibitor use and vitamin b12 deficiency in a lebanese population
International Journal of Development Research
Proton pump inhibitor use and vitamin b12 deficiency in a lebanese population
Received 21st January, 2018; Received in revised form 27th February, 2018; Accepted 29th March, 2018; Published online 30th April, 2018
Copyright © 2018, Elias Makhoul and Hani Waked. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Vitamin B12 is a crucial B vitamin. It is needed for nerve tissue health, brain function, and the production of red blood cells. Vitamin B12 deficiency is common, especially among the older population (1). The clinical manifestations and complications of vitamin B12 deficiency result from the effects of low vitamin B12 levels on the body systems, including: impaired cognition, depression, delusions, sensory loss, autonomic dysfunction, pancytopenia, macrocytosis, and cardiomyopathy. (2). Proton Pump Inhibitors are among the most commonly prescribed medications, and their use has increased in the recent years (4). Medications that reduce gastric acid may decrease vitamin B12 absorption since gastric acid plays a role in dissociation of vitamin B12 from food proteins, and the reduction of the production of intrinsic factor which impairs vitamin B12 absorption. (5). Several studies reported an association between long-term PPI use and increased risk of developing vitamin B12 deficiency (6). In our study, we performed the case-control method to evaluate the relationship between the use of PPIs and the risk of vitamin B12 deficiency, based on a sample from the Lebanese population.